SCHEMBL1688005

SCHEMBL1688005

Oc1ccc(C2CCCCc3c(F)cccc3O2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 11/20 0.46
ESR1 P03372 10/20 0.46
CYP3A4 P08684 3/20 0.41
NPC1 O15118 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
LTA4H P09960 5/20 0.40
CYP19A1 P11511 3/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
YES1 P07947 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1688041 0.99 ESR2 (0.45) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL1688043 0.80 ESR1 (0.42) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL1687994 0.77 ESR2 (0.57) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL1688018 0.76 ESR2 (0.56) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL1688033 0.72 ESR2 (0.62) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL22882228 0.69 ESR1 (0.42) ESR2ESR1CYP19A1
SCHEMBL6261080 0.69 ESR2 (0.71) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL29974353 0.69 ESR2 (0.71) ESR2ESR1CYP3A4NPC1ADORA3
SCHEMBL1688038 0.68 MEN1 (0.34) ESR2ESR1CYP3A4MAPK1MEN1
SCHEMBL13885028 0.66 ESR2 (0.41) ESR2ESR1CYP3A4NPC1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2012-04-12 US disclosed
US-8101651-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2012-01-24 US disclosed
US-20090131510-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. 2009-05-21 US disclosed
WO-2009055734-A1 CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA ESR2 2/4885ESR1 6/4885CYP3A4 2174/4885
US-20090131510-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA ESR2 2/4885ESR1 6/4885CYP3A4 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.